Influenza A Infections Market is Projected to Reach USD 10 Billion by 2036, Driven by Rising Disease Burden, Next-generation Vaccines, and Novel Antiviral Therapies

Influenza A Infections Market is Projected to Reach USD 10 Billion by 2036, Driven by Rising Disease Burden, Next-generation Vaccines, and Novel Antiviral Therapies | DelveInsight https://www.delveinsight.com/sample-request/influenza-a-infections-market https://www.delveinsight.com/sample-request/influenza-a-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr https://www.delveinsight.com/sample-request/influenza-a-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr https://www.abnewswire.com/email_contact_us.php?pr=influenza-a-infections-market-is-projected-to-reach-usd-10-billion-by-2036-driven-by-rising-disease-burden-nextgeneration-vaccines-and-novel-antiviral-therapies-delveinsight https://www.delveinsight.com/ DelveInsight's latest report, "Influenza A Infections Market Insights, Epidemiology and Market Forecast - 2036," provides a comprehensive analysis of the Influenza A market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the Influenza A market size was approximately USD 5,000 million in 2025 and is projected to reach approximately USD 10,000 million by 2036, growing at a CAGR of 7.9% during 2026-2036.(Albany, New York)- 7th Sep 2026 - DelveInsight's latest report, "Influenza A Infections Market Insights, Epidemiology and Market Forecast - 2036," provides a comprehensive analysis of the Influenza A market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the Influenza A market size was approximately USD 5,000 million in 2025 and is projected to reach approximately USD 10,000 million by 2036, growing at a CAGR of 7.9% during 2026-2036.Influenza A viruses are the only influenza viruses known to cause flu pandemics and include circulating subtypes such as A(H1N1) and A(H3N2). The substantial global disease burden, continued need for annual vaccination, limitations in vaccine effectiveness, antiviral resistance, and development of next-generation vaccines and novel antivirals are expected to drive market growth through 2036.Key Takeaways from the Influenza A Infections MarketThe Influenza A market size was approximately USD 5,000 million in 2025 and is projected to reach approximately USD 10,000 million by 2036, registering a 7.9% CAGR during 2026-2036.The United States accounted for the largest Influenza A market size among the 7MM in 2025, while Spain accounted for the lowest.Influenza A viruses contribute substantially to the global burden of seasonal influenza and are responsible for influenza pandemics.The vaccinated pool in the United States in 2025 was segmented across children, adolescents, adults, and pregnant women, with the highest vaccination levels observed among adults aged 18-49 years.The estimated influenza vaccine failure rate in the United States was approximately 70% in 2025, highlighting continued challenges in achieving effective protection against infection.XOFLUZA (baloxavir marboxil), developed by Roche and Shionogi, is an important approved antiviral option and is administered as a single oral dose.The Influenza A pipeline includes promising candidates such as CD388, mRNA-1010, Flu Pandemic mRNA (GSK4382276A), and CC-42344.Next-generation mRNA-based influenza vaccines are advancing through late-stage development and regulatory pathways, potentially enabling faster strain adaptation and scalable vaccine production.Key companies involved in the Influenza A market include Roche, BioCryst Pharmaceuticals, Seqirus, Moderna, Merck, GlaxoSmithKline, Cocrystal Pharma, Cidara Therapeutics, and others.Keen to know more about the Influenza A Infections Market Report?Key Factors Driving the Influenza A Infections MarketRising Global Disease BurdenInfluenza A contributes to a substantial global disease burden, with seasonal epidemics resulting in millions of infections and significant morbidity and mortality. The continuing burden of disease creates sustained demand for preventive vaccines, antiviral therapies, and improved diagnostic technologies.Growing Opportunities in Vaccines and Antiviral TherapiesInnovation in influenza prevention and treatment is creating new opportunities within the market. The development of mRNA-based vaccines, universal influenza vaccine platforms, novel antivirals, and improved diagnostic technologies is expected to expand treatment and prevention options. Increased focus on immunization and pandemic preparedness is also supporting market development.Increasing Development of Next-generation mRNA VaccinesNext-generation mRNA influenza vaccines, including mRNA-1010 from Moderna, are advancing through clinical development and regulatory review. These platforms offer the potential for faster strain adaptation and scalable manufacturing compared with conventional vaccine technologies.Growing Focus on Novel Antiviral MechanismsThe Influenza A pipeline includes candidates targeting different stages of viral replication. CC-42344, for example, is an investigational PB2 inhibitor designed to interfere with the influenza polymerase complex. Meanwhile, CD388 represents an emerging neuraminidase-targeting approach being evaluated in Phase III development.Continued Need to Address Unmet Medical NeedsDespite the availability of vaccines and antiviral therapies, limitations such as variable vaccine effectiveness, antiviral resistance, high disease burden, and the need to modernize vaccine production remain important unmet needs. These challenges are encouraging continued investment in innovative preventive and therapeutic approaches.Competitive LandscapeThe Influenza A treatment landscape consists of marketed antiviral therapies and vaccines alongside a growing pipeline of next-generation treatments and preventive approaches.Approved and marketed therapies include XOFLUZA (baloxavir marboxil) from Roche, RAPIVAB (peramivir) from BioCryst Pharmaceuticals, and FLUAD QUADRIVALENT from Seqirus. XOFLUZA is a single-dose oral antiviral that inhibits the cap-dependent endonuclease required for viral replication, while RAPIVAB is an intravenous neuraminidase inhibitor.The emerging pipeline includes CC-42344 from Cocrystal Pharma, CD388 from Cidara Therapeutics, mRNA-1010 from Moderna, and Flu Pandemic mRNA (GSK4382276A) from GlaxoSmithKline. These candidates employ different approaches, including PB2 inhibition, neuraminidase inhibition, and mRNA-based vaccination.Recent Developments in the Influenza A MarketMay 2026: Lupin Limited received approval from China's National Medical Products Administration for Oseltamivir Phosphate for Oral Suspension (6 mg/mL) for the treatment and prevention of Influenza A and B in pediatric patients and adults.February 2026: Cidara Therapeutics announced that MK-1406 (CD388) was being evaluated in the Phase III ANCHOR study.January 2026: Merck announced the successful completion of its acquisition of Cidara Therapeutics through a cash tender offer.March 2026: Cocrystal Pharma announced plans to continue development of oral CC-42344 as a treatment for pandemic and seasonal Influenza A through an additional Phase IIa study.February 2026: The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for mCombriax, a Moderna vaccine for the prevention of influenza.April 2025: Roche announced publication of a detailed Phase III CENTERSTONE analysis of XOFLUZA in the New England Journal of Medicine, reporting a reduction in influenza virus transmission.What is Influenza A?Influenza A is a viral respiratory infection caused by influenza A viruses. These viruses are classified according to two surface proteins: hemagglutinin (H) and neuraminidase (N). There are currently 18 known hemagglutinin subtypes and 11 neuraminidase subtypes, with A(H1N1) and A(H3N2) among the influenza A subtypes that routinely circulate in humans.Influenza A viruses can undergo antigenic drift and antigenic shift. Antigenic shift represents a major change in viral surface antigens and can result in the emergence of a new subtype with pandemic potential.Diagnosis is generally based on clinical symptoms and can be confirmed through laboratory testing. Rapid Influenza Diagnostic Tests detect viral antigens, while more sensitive molecular methods such as RT-PCR can confirm influenza virus type and subtype. Rapid molecular assays can provide results in approximately 20 minutes.Current Treatment LandscapeTreatment depends on disease severity and patient risk factors. Uncomplicated seasonal influenza is generally managed with symptomatic treatment, while high-risk patients may require antiviral therapy. Antiviral treatment such as oseltamivir is particularly important when administered early after symptom onset.For severe disease, including influenza-associated pneumonia or sepsis, immediate antiviral treatment is required. Recommended antiviral options include oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Vaccination remains the most effective preventive measure against severe influenza disease.Despite the availability of established therapies, the market continues to face unmet needs related to variable vaccine effectiveness, antiviral resistance, high disease burden, and the need for improved vaccine production technologies.Influenza A Epidemiology SegmentationThe Influenza A epidemiology analysis covers:Total Vaccinated Pool of Influenza ATotal Influenza Vaccine Failure CasesTotal Influenza A Positive CasesStrain-specific Cases of Influenza AAccording to DelveInsight, the United States recorded the highest Influenza A market size among the 7MM in 2025. In the United States, the vaccinated population was analyzed across children aged 0-4 and 5-12 years, adolescents aged 13-17 years, adults aged 18-49, 50-64, and greater than or equal to 65 years, and pregnant women.In 2025, the estimated Influenza vaccine failure rate in the United States was approximately 70%. In Japan, secondary analysis of surveillance data indicated an average of approximately 196,895 weekly influenza cases in November 2025, corresponding to an average of 51.12 cases per medical institution. In Europe, A(H1N1)pdm09 represented approximately 57-93% of influenza A cases in 2024.Scope of the Influenza A Infections Market ReportStudy Period: 2022-2036Historical Year: 2022-2025Forecast Period: 2026-2036Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and JapanMarket CAGR: 7.9% during 2026-2036Market Segmentation: Region/Geographies and Drugs/TherapiesEpidemiology Segmentation: Total vaccinated pool of Influenza A, total influenza vaccine failure cases, total Influenza A positive cases, and strain-specific Influenza A casesKey Companies Covered: Roche, BioCryst Pharmaceuticals, Seqirus, Moderna, Merck (Cidara Therapeutics), GlaxoSmithKline, Cocrystal Pharma, and othersKey Therapies Covered: mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), GSK5536522, GSK5475152, CC-42344, and othersMarket Analysis: KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needsMarket Assessment: Current treatment practices, clinical development analysis, emerging drug product profiles, market attractiveness, market drivers and barriers, patient burden, treatment addressable market, competitive landscape, pricing trends, drug adoption/uptake, and peak patient share analysisReport Insights: Influenza A patient population forecast, therapeutics market size, pipeline analysis, market size and trends, and current and forecasted market opportunity.To know more about the clinical trials, emerging therapies, market landscape, and therapeutic assessment of Influenza A:View the Influenza A Infections Market Report [Table of ContentsKey InsightsReport IntroductionExecutive SummaryKey EventsEpidemiology and Market Methodology of Influenza AInfluenza A Market Overview at a GlanceDisease Background and Overview of Influenza ATypes of Influenza AMolecular Classification of Influenza ACausesSigns and SymptomsDiagnosisTreatment and ManagementUnmet NeedsEpidemiologyEpidemiology ForecastDrug Analysis and Competitive LandscapeMarketed/Approved TherapiesEmerging TherapiesDrug UptakeMarket Access and ReimbursementPricing and Cost AnalysisKOL ViewsSWOT and Conjoint AnalysisMarket ForecastMarket Drivers and BarriersAppendixMethodologyAbout DelveInsightAbout DelveInsightDelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail:Send Email [Phone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NevadaCountry: United StatesWebsite:Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com